Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma: 4-year outcomes
Introduction: This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG). Methods: Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
February 23, 2018
|
| In: |
Advances in therapy
Year: 2018, Jahrgang: 35, Heft: 3, Pages: 395-407 |
| ISSN: | 1865-8652 |
| DOI: | 10.1007/s12325-018-0666-4 |
| Online-Zugang: | Verlag, Pay-per-use, Volltext: https://doi.org/10.1007/s12325-018-0666-4
|
| Verfasserangaben: | Jonathan S. Myers, Imran Masood, Dana M. Hornbeak, Jose I. Belda, Gerd Auffarth, Anselm Jünemann, Jane Ellen Giamporcaro, Jose M. Martinez-de-la-Casa, Iqbal Ike K. Ahmed, Lilit Voskanyan, L. Jay Katz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1683970667 | ||
| 003 | DE-627 | ||
| 005 | 20230426071232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191202s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-018-0666-4 |2 doi | |
| 035 | |a (DE-627)1683970667 | ||
| 035 | |a (DE-599)KXP1683970667 | ||
| 035 | |a (OCoLC)1341279295 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Myers, Jonathan S. |e VerfasserIn |0 (DE-588)1200909909 |0 (DE-627)1683989422 |4 aut | |
| 245 | 1 | 0 | |a Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma |b 4-year outcomes |c Jonathan S. Myers, Imran Masood, Dana M. Hornbeak, Jose I. Belda, Gerd Auffarth, Anselm Jünemann, Jane Ellen Giamporcaro, Jose M. Martinez-de-la-Casa, Iqbal Ike K. Ahmed, Lilit Voskanyan, L. Jay Katz |
| 264 | 1 | |c February 23, 2018 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.12.2019 | ||
| 520 | |a Introduction: This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG). Methods: Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with OAG and IOP ≥ 18 mmHg after prior trabeculectomy and while taking 1-3 glaucoma medications. Subjects received two iStent® trabecular micro-bypass stents, one iStent Supra® suprachoroidal stent, and postoperative travoprost. Postoperative IOP was measured with medication and annually following medication washouts. Performance was measured by the proportion of eyes with ≥ 20% IOP reduction on one medication (the protocol-specified prostaglandin) versus preoperative medicated IOP (primary outcome); and the proportion of eyes with postoperative IOP ≤ 15 and ≤ 18 mmHg on one medication (secondary outcome). Additional clinical and safety data included medications, visual field, pachymetry, gonioscopy, adverse events, visual acuity, and slit-lamp and fundus examinations. Results: Preoperatively, mean medicated IOP was 22.0 ± 3.1 mmHg on 1.2 ± 0.4 medications, and mean unmedicated IOP was 26.4 ± 2.4 mmHg. Postoperatively, among eyes without later cataract surgery, mean medicated IOP at all visits through 48 months was ≤ 13.7 mmHg (≥ 37% reduction), and annual unmedicated IOP was ≤ 18.4 mmHg (reductions of ≥ 30% vs. preoperative unmedicated IOP and ≥ 16% vs. preoperative medicated IOP). At all postoperative visits among eyes without additional surgery or medication, ≥ 91% of eyes had ≥ 20% IOP reduction on one medication versus preoperative medicated IOP. At month 48, 97 and 98% of eyes achieved IOP ≤ 15 and ≤ 18 mmHg, respectively, on one medication. Six eyes required additional medication, no eyes required additional glaucoma surgery, and safety measurements were favorable throughout follow-up. Conclusion: IOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease. | ||
| 650 | 4 | |a Glaucoma | |
| 650 | 4 | |a iStent | |
| 650 | 4 | |a iStent Supra | |
| 650 | 4 | |a Microinvasive glaucoma surgery (MIGS) | |
| 650 | 4 | |a Ophthalmology | |
| 650 | 4 | |a Prostaglandin | |
| 650 | 4 | |a Refractory glaucoma | |
| 650 | 4 | |a Suprachoroidal | |
| 650 | 4 | |a Trabecular | |
| 700 | 1 | |a Auffarth, Gerd U. |d 1964- |e VerfasserIn |0 (DE-588)123385261 |0 (DE-627)577130420 |0 (DE-576)293687277 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Tarporley : Springer Healthcare Communications, 2000 |g 35(2018), 3, Seite 395-407 |h Online-Ressource |w (DE-627)563170433 |w (DE-600)2421646-X |w (DE-576)306836041 |x 1865-8652 |7 nnas |a Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma 4-year outcomes |
| 773 | 1 | 8 | |g volume:35 |g year:2018 |g number:3 |g pages:395-407 |g extent:13 |a Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma 4-year outcomes |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s12325-018-0666-4 |x Verlag |x Resolving-System |z Pay-per-use |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191202 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 123385261 |a Auffarth, Gerd U. |m 123385261:Auffarth, Gerd U. |d 910000 |d 910900 |e 910000PA123385261 |e 910900PA123385261 |k 0/910000/ |k 1/910000/910900/ |p 5 | ||
| 999 | |a KXP-PPN1683970667 |e 3555586378 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"13 S."}],"recId":"1683970667","relHost":[{"disp":"Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma 4-year outcomesAdvances in therapy","title":[{"title":"Advances in therapy","title_sort":"Advances in therapy"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"text":"35(2018), 3, Seite 395-407","year":"2018","pages":"395-407","issue":"3","volume":"35","extent":"13"},"id":{"eki":["563170433"],"issn":["1865-8652"],"zdb":["2421646-X"]},"origin":[{"dateIssuedDisp":"2000-","dateIssuedKey":"2000","publisherPlace":"Tarporley","publisher":"Springer Healthcare Communications"}],"language":["eng"],"pubHistory":["Nachgewiesen 17.2000 -"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"563170433"}],"note":["Gesehen am 02.12.2019"],"language":["eng"],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"February 23, 2018"}],"id":{"eki":["1683970667"],"doi":["10.1007/s12325-018-0666-4"]},"person":[{"family":"Myers","display":"Myers, Jonathan S.","role":"aut","given":"Jonathan S."},{"given":"Gerd U.","family":"Auffarth","display":"Auffarth, Gerd U.","role":"aut"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma","title_sort":"Prospective evaluation of two iStent® trabecular stents, one iStent Supra® suprachoroidal stent, and postoperative prostaglandin in refractory glaucoma","subtitle":"4-year outcomes"}],"name":{"displayForm":["Jonathan S. Myers, Imran Masood, Dana M. Hornbeak, Jose I. Belda, Gerd Auffarth, Anselm Jünemann, Jane Ellen Giamporcaro, Jose M. Martinez-de-la-Casa, Iqbal Ike K. Ahmed, Lilit Voskanyan, L. Jay Katz"]}} | ||
| SRT | |a MYERSJONATPROSPECTIV2320 | ||